Brown adipose tissue activation on PET-CT in patients diagnosed with pheochromocytomas or Cushings syndrome.

Recruiting

• Conditions: metabolic syndrome; obesity; 10001353; 10018424

• Registration Number: NL-OMON37498
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

-Documented diagnosis of pheochromocytoma or cushing syndrome
-Signed informed consent
-3 months stable medication, described for other comorbidities,
-Female or Male subjects of 18 years or older

Exclusion Criteria

-BMI>35
-Use of a PPAR-γ agonist
-Use of insulin
-If female, pregnancy or breast feeding
-Drug or alcohol dependence or abuse
-Participation in a trial of an experimental drug or device within 60 days prior to screening for pheochromocytoma or Cushing syndrome.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>BAT activity measured by FDG-PET.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Insulin sensitivity measured by a modified insulin tolerance test<br /><br>- Study body composition before and after treatment, measured by DXA scan<br /><br>- Tissue analysis of perirenal BAT obtained during adrenalectomy.<br /><br>- Study serum BAT activity markers. </p><br>